1,144 results on '"Jung, Sin-Ho"'
Search Results
2. Efficacy of probiotic treatment as post-exposure prophylaxis for COVID-19: A double-blind, Placebo-Controlled Randomized trial
3. ASO Visual Abstract: Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does It Matter?
4. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
5. Quantifying the Opportunity Cost of Neurosurgical Resident Education
6. Long-term outcomes of aortic root operations in the United States among Medicare beneficiaries
7. Confidence intervals for odds ratio from multistage randomized phase II trials
8. Estimation of the odds ratio from multi‐stage randomized trials
9. Sample size calculation for comparing two ROC curves
10. Prediction model to estimate overall survival benefit of postoperative radiotherapy for resected major salivary gland cancers
11. Sample size calculation for clustered survival data under subunit randomization
12. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
13. Impact of Imaging Frequency on Progression Free Survival in Alliance Trials Enrolling Patients with Follicular Lymphoma
14. Improving Patient Outcomes with a Mobile Digital Health Platform for Patients Undergoing Transcatheter Aortic Valve Replacement
15. Bacteremia in solid organ transplant recipients as compared to immunocompetent patients: Acute phase cytokines and outcomes in a prospective, matched cohort study
16. Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma
17. A 10-year trend in income disparity of cardiovascular health among older adults in South Korea
18. Sample Size Estimation and Power Analysis: Longitudinal Data
19. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
20. LASSO and Elastic Net Tend to Over-Select Features
21. TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET)
22. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
23. A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance])
24. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
25. Regional anesthesia is associated with improved metastasis free survival after surgical resection of bone sarcomas.
26. A pilot study to assess the feasibility of a remotely monitored high-intensity interval training program prior to allogeneic hematopoietic stem cell transplantation.
27. The Contribution of Material, Behavioral, Psychological, and Social-Relational Factors to Income-Related Disparities in Cardiovascular Risk Among Older Adults
28. Revisiting flow augmentation bypass for cerebrovascular atherosclerotic vaso-occlusive disease: Single-surgeon series and review of the literature
29. Survival and tumor characteristics of patients presenting with single primary versus second primary melanoma lesions
30. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)
31. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy
32. Home-Based Hematopoietic Cell Transplantation in the United States
33. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
34. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma
35. A Copula Approach for Detecting Prognostic Genes Associated with Survival Outcome in Microarray Studies
36. Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non–Small Cell Lung Cancer
37. Design of phase II non-inferiority trials
38. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
39. Supplementary table TS1 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
40. Supplementary figure FS2 from Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma
41. Supplementary Table 1 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
42. Supplemental Figure 4 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
43. Data from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
44. Supplemental Figure 3 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
45. Supplementary Figure 1 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
46. Supplemental Figure 2 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
47. Data from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
48. Supplemental Figure 5 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
49. Supplementary Figure 3 from Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma
50. Supplemental Figure 1 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.